Table 1. Overview of publications on case-series investigating the effect of PSMA RLT (the overview makes no claim to completeness).
| RLT | Author | Pts, n | Lines of treatment | CTX-naive pts | OS | PFS | PSA-decline >50% | Toxicity | |
|---|---|---|---|---|---|---|---|---|---|
| III | IV | ||||||||
| 131I-MIP-1095 | Zechmann et al. (18)† | 28 | N/A | N/A | N/A | N/A | 17/28 (61%) (BR) | – | – |
| 177Lu-PSMA-617 | Kratochwil et al. (7)† | 1 | N/A | N/A | N/A | N/A | 1/1 (100%) (BR) | N/A | N/A |
| Kratochwil et al. (19) | 30 | >1 | 16 (53%) | N/A | N/A | 13/30 (43%) (W8) | Anemia, 1 (3%) TP, 1 (3%) | – | |
| Ahmadzadehfar et al. (20) | 24 | >1 | 14 (58%) | N/A | N/A | 13/22 (60%) (BR) | Anemia, 2 (8%) | – | |
| Rahbar et al. (21)‡ | 82 | >2 | 30 (37%) | N/A | N/A | 23/74 (31%) (BR) | Anemia, 1 (1%) TP, 1 (1%) | – | |
| Hofman et al. (13) | 30 | >2 | 4 (13%) | 13.5 | 7.6 | 17/30 (57%) (BR) | Anemia, 4 (13%) TP, 3 (10%) | TP 1 (3%) | |
| Violet et al. (22) | 50 | >2 | 8 (16%) | 13.3 | 6.9 | 32/50 (64%) (BR) | Anemia, 5 (10%) TP 4 (8%) | TP 1 (3%) | |
| Hofman et al. (17) | 98 | >1 | 0 | N/A | N/A | 64/98 (66%) (BR) | Neutropenia 4 (4%), TP 11 (11%) | ||
| 177Lu-PSMA-I&T | Weineisen et al. (8)† | 2 | N/A | N/A | N/A | N/A | 1/1 (100%) (BR) | – | – |
| Baum et al. (23) | 56 | >3 | 31 (55%) | 28 | 13.7 | 33/56 (59%) (BR) | – | – | |
| Heck et al. (4) | 22 | >2 | 0 | N/A | N/A | 10/18 (56%) (BR) | – | – | |
| Heck et al. (5) | 100 | >2 | 16 (16%) | 12.9 | 4.1 | 38/100 (38%)(BR) | Anemia, 9 (9%) neutropenia, 6 (6%), TP, 4 (4%) | ||
| 177Lu-PSMA-I&T/617 | Barber et al. (24) | 167 | 1–2 | 84 (50%) | >10.7 | >6 | 65/132 (49%) (AR) | Anemia 8 (4%), leucopenia 2 (2%), TP 4 (2%) | – |
| 225Ac-PSMA-617 | Kratochwil et al. (25)† | 2 | >4 | 0 | N/A | N/A | 2/2 (100%) (BR) | Xerostomia 1 (50%) | – |
| Kratochwil et al. (12) | 40 | >3 | 12 (30%) | >12 | 6 | 24/38 (63%) (BR) | Xerostomia 4 (10%) | – | |
| Sathekge et al. (26) | 73 | 1–2 | 36 (49%) | 18 | 15.2 | 51/73 (70%) | Anemia 5 (7%), leucopenia 2 (3%), renal failure 3 (4%) | Renal failure 2 (3%) | |
AR, any response; BR, best response. CTX, chemotherapy; CX, cycles. N/A, not available. Pts, patients. TP, thrombopenia. W8, after 8 weeks. †, original publication/first description of respective RLT; ‡, publication includes patients reported in Ahmadzadehfar et al., Oncotarget 2016; §, publication includes patients reported in Hofman et al., Lancet Oncol 2018.